emily oster glp 1 Our idea of a good time? Bringing our community together for real talk about GLP-1s, pregnancy, menopause, weight loss, and everything in between. #ICYMI, last week at Forty Carrots, and Community Focus: Guest Dr. Emily

doi: 10.1146/annurev-pathol-011110-130158 185 Matuz-MaresD.Riveros-RosasH.Vilchis-LanderosM

Currently, there is an ongoing randomised double-masked placebo-controlled trial, the SUMMIT trial, studying the efficacy and safety of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and GLP-1 receptors, versus placebo in HFpEF patients with obesity (NCT04847557)

5.2.2 Mitochondrial dysfunction exacerbates ROS production: a vicious cycle Mitochondrial dysfunction both amplifies ROS generation and impairs antioxidant defense, establishing a self-perpetuating cycle of oxidative injury and organelle deterioration (Chen T-H

This opens the door to a new era of oral small molecule therapies that target the well-validated GLP-1R pathway for metabolic health